Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3647-3651

  Pillai, A A ^a   Lee, V S ^a   Wang, E ^a   Rinella, M E ^a   Levitsky, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; CYTOPENIA; DATA ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EARLY VIROLOGICAL RESPONSE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART ARREST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; LIVER VEIN THROMBOSIS; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PREDICTION; PRIORITY JOURNAL; RECURRENT INFECTION; SEPSIS; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL PHENOMENA AND FUNCTIONS;

AGED; ANTIVIRAL AGENTS; CHICAGO; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649487980     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.06.018     Document Type: Article

References (45)

1. E. Gane The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients Liver Transpl 9 2003 S28
2. H. Rodriguez-Luna, and D.D. Douglas Natural history of hepatitis C following liver transplantation Curr Opin Infect Dis 17 2004 36
3. S.J. Pelletier, J.C. Iezzoni, and T.D. Crabtree Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transminase levels versus necroinflammatory activity Liver Transpl 6 2000 44
4. M. Prieto, M. Berenguer, and J.M. Rayon High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250
5. E.J. Gane, B.C. Portmann, and N.V. Naoumov Long-term outcome of hepatitis C infection after liver transplantation N Engl Med 334 1996 815
6. C. Feray, L. Caccamo, and G.J. Alexander European collaborative study on factors influencing outcome after liver transplantation for hepatitis C European Concerted Action on Viral Hepatitis (EUROHEP) Group Gastroenterology 117 1999 619
7. L.M. Forman, J.D. Lewis, and J.A. Berlin The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889
8. N. Yilmaz, M.L. Shiffman, and R.T. Stravitz A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transpl 13 2007 975
9. U.P. Neumann, T. Berg, and M. Bahra Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830
10. M. Sebagh, K. Rifai, and C. Feray All liver recipients benefit from the protocol 10-year liver biopsies Hepatology 37 2003 1293
11. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825
12. C. Niederau, S. Lange, and T. Heintges Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 1998 1687
13. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274
14. M. Berenguer, A. Palau, and V. Aguilera Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679
15. F.P. Picciotto, G. Tritto, and A.G. Lanza Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation J Hepatol 46 2007 459
16. T. Berg, C. Sarrazin, and E. Herrmann Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy Hepatology 37 2003 600
17. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634
18. V. Ortiz, M. Berenguer, and J.M. Rayon Contribution of obesity to hepatitis C- related fibrosis progression Am J Gastroenterol 97 2002 2408
19. L.F. Hourigan, G.A. Macdonald, and D. Purdie Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis Hepatology 29 1999 121
20. B.L. Bressler, M. Guindi, and G. Tomlinson High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C Hepatology 38 2003 639
21. M.R. Charlton, P.J. Pockros, and S.A. Harrison Impact of obesity on treatment of chronic hepatitis C Hepatology 43 2006 1177
22. L. Fartoux, A. Poujol-Robert, and J. Guechot Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C Gut 54 2005 1003
23. J.M. Hui, A. Sud, and G.C. Farrell Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected] Gastroenterology 125 2003 1695
24. M. Romero-Gomez, M. Del Mar Viloria, and R.J. Andrade Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636
25. A. Zekry, J.G. McHutchison, and A.M. Diehl Insulin resistance and steatosis in hepatitis C virus infection Gut 54 2005 903
26. I.A. Hanouneh, A.E. Feldstein, and R. Lopez Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection Clin Gastroenterol Hepatol 6 2008 584
27. M. Shaheen, D. Echeverry, and M.G. Oblad Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III] Diabetes Res Clin Pract 75 2007 320
28. S. Ramirez, S. Perez-Del-Pulgar, and X. Forms Virology and pathogenesis of hepatitis C virus recurrence Liver Transpl 14 suppl 2 2008 S27
29. M. Berenguer, M. Prieto, and J.M. Rayon Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852
30. J. Pruthi, K.A. Medkiff, and K.T. Esrason Analysis of causes of death in liver transplant recipients who survived more than 3 years Liver Transpl 7 2001 811
31. G. Fattovich, G. Giustina, and F. Degos Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463
32. J. Dumortier, J.Y. Scoazec, and P. Chevallier Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination J Hepatol 40 2004 669
33. L. Castells, V. Vargas, and H. Allende Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation J Hepatol 43 2005 53
34. M. Berenguer, A. Palau, and A. Fernandez Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C Liver Transpl 12 2006 1067
35. E. Oton, R. Barcena, and J.M. Moreno-Planas Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG- interferon and ribavirin Am J Transplant 6 2006 2348
36. J.A. Carrion, M. Navasa, and M. Garcia-Retortillo Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study Gastroenterology 132 2007 1746
37. I. Fernandez, J.C. Meneu, and F. Colina Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation Liver Transpl 12 2006 1805
38. P. Sharma, J.A. Marrero, and R.J. Fontana Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence Liver Transpl 13 2007 1100
39. U. Neumann, G. Puhl, and M. Bahra Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin Transplantation 82 2006 43
40. T. Bizollon, P. Pradat, and J.Y. Mabrut Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C Am J Transplant 5 2005 1909
41. M. Bahra, U.P. Neumann, and D. Jacob Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy) Transplantation 83 2007 351
42. A. Kornberg, B. Kupper, and A. Tnnapfel Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C Transplantation 86 2008 469
43. I.A. Hanouneh, A.E. Feldstein, and A.J. McCullough The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation Liver Transpl 14 2008 1287
44. B.J. Veldt, J.J. Poterucha, and K.D. Watt Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C Am J Transplant 9 2009 1406
45. A.L. Mindikoglu, A. Regev, and P.Y. Casanova-Romero The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation Transplant Proc 38 2006 1440